Jérôme Beaufays and Laurence Lins contribute equally to the paper.
Research Article
In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues
Article first published online: 27 OCT 2011
DOI: 10.1002/psc.1410
Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.
Additional Information
How to Cite
Beaufays, J., Lins, L., Thomas, A. and Brasseur, R. (2012), In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues. J. Peptide Sci., 18: 17–24. doi: 10.1002/psc.1410
Publication History
- Issue published online: 26 DEC 2011
- Article first published online: 27 OCT 2011
- Manuscript Accepted: 1 JUL 2011
- Manuscript Revised: 14 JUN 2011
- Manuscript Received: 30 MAR 2011
Keywords:
- cyclic peptides;
- non-natural peptides;
- structure prediction;
- Boltzmann-Stochastic;
- modeling
We extended the use of Peplook, an in silico procedure for the prediction of three-dimensional (3D) models of linear peptides to the prediction of 3D models of cyclic peptides and thanks to the ab initio calculation procedure, to the calculation of peptides with non-proteinogenic amino acids. Indeed, such peptides cannot be predicted by homology or threading. We compare the calculated models with NMR and X-ray models and for the cyclic peptides, with models predicted by other in silico procedures (Pep-Fold and I-Tasser). For cyclic peptides, on a set of 38 peptides, average root mean square deviation of backbone atoms (BB-RMSD) was 3.8 and 4.1 Å for Peplook and Pep-Fold, respectively. The best results are obtained with I-Tasser (2.5 Å) although evaluations were biased by the fact that the resolved Protein Data Bank models could be used as template by the server. Peplook and Pep-Fold give similar results, better for short (up to 20 residues) than for longer peptides. For peptides with non-proteinogenic residues, performances of Peplook are sound with an average BB-RMSD of 3.6 Å for ‘non-natural peptides’ and 3.4 Å for peptides combining non-proteinogenic residues and cyclic structure. These results open interesting possibilities for the design of peptidic drugs. Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.

1099-1387/asset/PSC_left.gif?v=1&s=8a12eca29ad625411fd707f9f6fdb57a8350cf0c)
1099-1387/asset/PSC_right.gif?v=1&s=181d84d31366428b2bf1cdbbd84306433ea461b3)
